Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash & Equivalents (2018 - 2025)

10x Genomics (TXG) has disclosed Cash & Equivalents for 8 consecutive years, with $474.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 37.75% to $474.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $474.0 million through Dec 2025, up 37.75% year-over-year, with the annual reading at $474.0 million for FY2025, 37.75% up from the prior year.
  • Cash & Equivalents hit $474.0 million in Q4 2025 for 10x Genomics, up from $432.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $622.0 million in Q2 2021 to a low of $219.7 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $397.8 million across 5 years, with a median of $368.2 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 83.01% in 2021 and later plummeted 62.59% in 2022.
  • Year by year, Cash & Equivalents stood at $587.4 million in 2021, then tumbled by 62.59% to $219.7 million in 2022, then surged by 63.5% to $359.3 million in 2023, then decreased by 4.24% to $344.1 million in 2024, then soared by 37.75% to $474.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for TXG at $474.0 million in Q4 2025, $432.5 million in Q3 2025, and $397.7 million in Q2 2025.